Capital Fund Management (CFM)
ATRA icon

Capital Fund Management (CFM)’s Atara Biotherapeutics ATRA Stock Holding History

Capital Fund Management (CFM)’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-630
Closed -$309K – 1256
2020
Q4 		$309K Buy
+630
New +$291K ﹤0.01% 1205

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capital Fund Management (CFM)'s ATRA Position: Q1 2021 in Review

Capital Fund Management (CFM) sold out of Atara Biotherapeutics (ATRA) in Q1 2021, closing a stake of 630 shares — an estimated $309K sold.

Capital Fund Management (CFM) first reported a position in ATRA in Q4 2020 and held it in 1 quarter. The position peaked at $309K in Q4 2020. 151 funds tracked by Wall St. Rank hold ATRA as of Q1 2021.

  • Capital Fund Management (CFM) reported no remaining Atara Biotherapeutics position as of Q1 2021 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 630 Atara Biotherapeutics shares in Q1 2021, an estimated $309K.
  • Capital Fund Management (CFM) first reported a position in Atara Biotherapeutics in Q4 2020 and held it in 1 quarter.
  • Capital Fund Management (CFM)'s Atara Biotherapeutics position peaked at $309K in Q4 2020.
  • 151 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2021.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2021, filed 14 May 2021.